Phase I clinical and pharmacologic trial of carboplatin daily for 5 days

D. A. van Echo, M. J. Egorin, M. Y. Whitacre, E. A. Olman, J. Aisner

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

Twenty-two patients with refractory tumors received 64 courses of iv bolus carboplatin every day x 5, every 4-5 weeks. All patients are evaluable for toxicity and 18 are evaluable for response. For solid tumor phase II studies, a dose of 77 mg/m2/day x 5 is recommended for patients who have received prior chemotherapy. Patients with no prior chemotherapy experience should receive 99 mg/m2/day x 5. The major dose-limiting side effect is dose-related thrombocytopenia. Courses of carboplatin on this schedule should be repeated every 5 weeks to avoid cumulative wbc count toxicity, since leukopenia frequently did not occur until Day 28. Other toxic effects observed were nausea and vomiting and lower-extremity myalgias and arthralgias. There was no evidence of hearing loss, mucosal damage, or changes in liver or renal function tests of any patient while in this study. Therapeutic responses were seen in four patients: one partial response in renal cancer of 9+ months' duration; one partial response in head and neck cancer of 7+ months' duration; and objective responses in melanoma and colorectal carcinoma of 6 months' duration.

Original languageEnglish (US)
Pages (from-to)1103-1114
Number of pages12
JournalCancer treatment reports
Volume68
Issue number9
StatePublished - Nov 1 1984
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I clinical and pharmacologic trial of carboplatin daily for 5 days'. Together they form a unique fingerprint.

  • Cite this

    van Echo, D. A., Egorin, M. J., Whitacre, M. Y., Olman, E. A., & Aisner, J. (1984). Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer treatment reports, 68(9), 1103-1114.